Using Telecytopathology for Diagnosing Pancreatic Cancer
Author Information
Author(s): Kim Burton, Chhieng David C, Crowe David R, Jhala Darshana, Jhala Nirag, Winokur Thomas, Eloubeidi Mohamad A, Eltoum Isam E
Primary Institution: Scripps Green Hospital/Clinic, Department of Pathology, La Jolla, California, USA
Hypothesis
Can real-time telecytopathology provide accurate diagnoses for pancreatic lesions compared to onsite evaluations?
Conclusion
Telecytopathology can serve as a valid substitute for onsite evaluation of pancreatic carcinoma by EUS-FNA.
Supporting Evidence
- Telecytopathology showed a Kappa value of 0.61 when compared to final diagnoses.
- Time spent for telecytopathology diagnosis averaged 7.5 minutes.
- Overall accuracy of EUS-FNA with onsite cytopathologists is high, with sensitivity and specificity reported between 77%-100%.
Takeaway
Doctors can use a special remote system to look at slides of pancreatic cancer samples and still get good results, just like if they were right there in the room.
Methodology
40 pancreatic lesions were re-evaluated using a telecytopathology system, comparing diagnoses made remotely to those made onsite.
Potential Biases
The prescreener had no formal cytology training, which could introduce bias in slide selection.
Limitations
The study relied on a small sample size and the experience of the prescreener, which may affect the accuracy of telepathology diagnoses.
Participant Demographics
Patients aged 31-62, with 19 males and 21 females.
Statistical Information
Confidence Interval
Kappa for telecytopathology vs onsite diagnosis: 0.65 (95% CI: 0.41–0.88); telecytopathology vs final diagnosis: 0.61 (95% CI: 0.37–0.85).
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website